Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic’s Resolute Integrity stent outperforms rival in new trial

Medtronic’s Resolute Integrity stent outperforms rival in new trial

4th November 2013

Medtronic has announced the results of a new clinical trial which underline the benefits its Resolute Integrity drug-eluting stent (DES) can offer over rival devices.

The stent was recently assessed in Dutch Peers, a head-to-head, randomised, controlled trial of third-generation durable-polymer DES offerings for the treatment of coronary artery disease in an all-comers patient population.

When compared to another leading device, it was found that Medtronic's device performed similarly on all measures except longitudinal strength – typically, a weakness of this type of stent – with the Resolute Integrity offering significant advantages in this regard.

Lead author Clemens von Birgelen, professor of cardiology at the University of Twente in the Netherlands, said: "A potential trade-off with the novel, flexible designs of third-generation stent platforms was thought to be reduced longitudinal device stability. However, our study did not find such a trade-off with the Resolute Integrity DES."

This comes after the company also recently reported positive data from Symplicity HTN-2, a study assessing the long-term benefits offered by its Symplicity renal denervation system.ADNFCR-8000103-ID-801656695-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.